# AOP Health

Source: https://onco.cc/companies/aop-health/  
OnCo record `aop-health` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AOP Health is a Vienna rare-disease company that brought ropeginterferon alfa-2b (Besremi) to the European market for polycythaemia vera and runs trials in myeloproliferative neoplasms and other rare conditions.

## Summary

AOP Health (formerly AOP Orphan Pharmaceuticals) is a privately held Austrian company focused on rare diseases and intensive care medicine. In cancer it licensed ropeginterferon alfa-2b from PharmaEssentia for Europe and other territories, obtained European approval for polycythaemia vera in 2019 under the name Besremi, and sponsors phase 3 trials of the drug in myeloproliferative neoplasms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: AOP Orphan Pharmaceuticals AG; AOP Orphan; AOP Orphan Pharmaceuticals
- Tags: ctgov-sponsor
- HQ: Vienna
- Type: pharma
- Website: https://www.aop-health.com

## Sources

- Official website: https://www.aop-health.com
- ClinicalTrials.gov: trials led by AOP Orphan Pharmaceuticals: https://clinicaltrials.gov/search?lead=AOP%20Orphan%20Pharmaceuticals

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Ropeginterferon alfa-2b](https://onco.cc/drugs/ropeginterferon-alfa-2b/)

---
JSON: https://onco.cc/api/v1/entities/aop-health.json